ReviewFrontiers in rehabilitation sciences2026
Non-pharmacological therapies for patients with lymphangioleiomyomatosis: a systematic review and meta-analysis.
Review in Frontiers in rehabilitation sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to systematically review non-pharmacological therapies for patients with lymphangioleiomyomatosis (LAM), and synthesize the effects of non-pharmacological therapies on 6-minute walking distance test (6MWDT), pulmonary function (FEV₁), and quality of life in LAM patients. Methods: The systematic review and meta-analysis design was used. Data were searched on Scopus, Web of Science, PubMed, Embase, OVID, CINAHL, CNKI and Wang Fang for studies published from August 2015 to August 2025 on non-pharmacological therapies for patients with LAM. Studies were screened using rigorous inclusion and exclusion criteria. Study quality was assessed using JBI study quality evaluation tools, and a stratified narrative synthesis was conducted based on intervention types, supplemented with a meta-analysis (excluding single-case report). Results: Five studies were eligible to be included in this study. Narrative synthesis showed that interventions with multicomponent, including high intensity aerobic and strength training, yoga, pulmonary rehabilitation and telemonitoring exercise, are beneficial for patients with LAM. Meta-analysis results (excluding the case report) showed that non-pharmacological therapies, particularly structured exercise programs, significantly increased physical activity tolerance of patients with LAM ( Discussion: Non-pharmacological therapies, especially physiotherapy, can improve patients with LAM's physical activity tolerance, enhancing their physical fitness and daily activity capacity. Compared with other alveolar and parenchymal diseases (e.g., tuberculosis, COPD), LAM patients show similar improvements in exercise tolerance but less significant improvements in lung function, which may be related to the unique cystic lung pathology of LAM. More effectively and innovatively designed research is needed to improve patients with LAM's pulmonary function and quality of life. Conclusions: This study not only demonstrates the potential value of non-pharmacological therapies in the management of patients with LAM, but also points the directions for future research. By further optimizing the interventions and expanding the sample size, we can achieve a comprehensive understanding of the long-term effects of non-pharmacological therapies in patients with LAM, eventually providing more effective treatment options for patients. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, PROSPERO system ID: CRD42024548486.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.